SecBot SecBot

HEPA

Hepion Pharmaceuticals, Inc.
OTC· Pharmaceutical Preparations· Inc. DE· CIK 0001583771 Biotech & Drug Discovery
$0.1281 −0.01 (−8.50%)
Oct 26 4:00 PM ET · prev $0.1400
1 year
+97.1%
from $0.0650 · Oct 27
30 days
+60.1%
from $0.0800
52-week range
$0.0350–0.1400
−9% from high · low Jan 30
Avg volume 20D
24.3K
Sep 29 spike 93.7K
Short interest
🔒 Subscribers only
Insider net
+$1.2M
6 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2025 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/4
Strongest MIXED Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences (GLS), a clinical-stage biotech…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    6 insiders bought $1.2M. No open-market sales.

  • InstitutionsMIXED

    Q2 2025: 1 added (0 new), 0 trimmed or exited.

  • TrendUPTREND

    44% above its 50-day average. New closing high $0.1400 on Oct 23.

Who's buying

13F· Q2 2025
0
new positions
0
exits
FundMoveSharesValue
OSAIC HOLDINGS, INC.ADD3—
VANGUARD GROUP INCTRIM50,251$23.6K
UBS Group AGDOUBLED14,032$6.6K
VANGUARD GROUP INCTRIM90,922$60.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Dec 2023
Recent actions
DateFirmActionRating
Dec 7, 2023Brookline Capital
DOWNGRADE
DOWNGRADEHold

Insider ledger

Form 4
$1.2M
bought · 6 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Sep 29, 2026
Fisher Danina
Director
BUY$10.0K
Sep 29, 2026
Fisher Danina
Director
BUY200,000 sh
Sep 3, 2026
LoPriore Vincent S
Executive Chairman
BUY12,500,000 sh
Aug 19, 2026
Purcell Michael J.
Director
AWARD299,000 sh
Aug 19, 2026
LoPriore Vincent S
Executive Chairman
AWARD1,345,500 sh
Aug 19, 2026
Stetz Gary S.
Interim CEO
AWARD1,345,500 sh
Aug 19, 2026
Appajosyula Sireesh
Chief Operating Officer
AWARD1,345,500 sh
Aug 19, 2026
Stetz Gary S. II
Director
AWARD299,000 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Kenneth Rickel, a director of Hepion Pharmaceuticals, filed an amended Schedule 13G disclosing beneficial ownership of…
SC 13G/A — Impact 3/10
Oct 9, 2026 SEC
Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences (GLS), a clinical-stage biotech developing…
8-K — Impact 6/10
Sep 29, 2026 Insider
Fisher Danina bought 200,000 shares
Director @ $0.0500 ($10.0K)
Sep 29, 2026 Insider
Fisher Danina bought 200,000 shares
Director
Sep 28, 2026 SEC
Hepion Pharmaceuticals dismissed its auditor, Grassi & Co., and engaged Rosenberg Rich Baker Berman P.A. as its new…
8-K — Impact 6/10
Sep 3, 2026 Insider
LoPriore Vincent S bought 12,500,000 shares
Executive Chairman
Jun 30, 2025 Inst.
OSAIC HOLDINGS, INC. — ADD
3 shares (—)
Dec 31, 2024 Inst.
VANGUARD GROUP INC — TRIM
50,251 shares ($23.6K)

SecBot reports

6 filings · 1 bullish · 1 bearish · 3 mixed · 1 neutral
All HEPA filing & press-release reports (6)